News & Updates

Among type 2 diabetes (T2D) patients on first-generation basal insulins (1BIs), a switch to either glargine or degludec in the real-world setting leads to marked improvements in glucose control without increasing the risk of hypoglycaemic events and weight gain, according to a study. Furthermore, the benefits seem to be comparable between the two second-generation basal insulins (2BIs).

In type 2 diabetes (T2D) patients with obesity, calorie restriction helps correct several cardiovascular (CV) risk factors and glomerular hyperfiltration, with the latter translating into a relative long-term stabilization of kidney function, according to a study.

Patients with symptomatic internal carotid artery (ICA) stenosis may fare well with revacept, a competitive antagonist of glycoprotein VI, as the drug helps reduce the incidence of stroke or death, transient ischaemic attack, and bleeding complications, among others, according to a study.

In patients with proton pump inhibitor (PPI)-refractory gastroesophageal reflux disease (GERD), add-on treatment with baclofen improves several reflux parameters, but only among those who are positive for symptom association probability, a study has found.

Bleeding and mortality risks are elevated in atrial fibrillation (AF) patients treated with nonvitamin K antagonist oral anticoagulant (NOAC) who are also using P-glycoprotein (P-gp) and CYP3A4 inhibitors, reports a study, noting the need for close monitoring of these individuals.

The novel neoadjuvant therapy S-1, an oral fluoropyrimidine agent containing tegafur, gimeracil, and oteracil potassium, yields promising survival outcomes in high-risk patients with resectable pancreatic ductal adenocarcinoma, a recent study has found.